Twist Bioscience (TWST) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$431.8M

Revenue (quarter)

$118.4M

Revenue growth (year over year)

+23.24%

Gross profit (trailing twelve months)

$224.4M

Gross margin

51.97%

Net income (trailing twelve months)

−$136.7M

Net income (quarter)

−$35.1M

Net income growth (year over year)

−271.90%

Net margin

−31.66%

Return on equity

−29.59%

EPS (trailing twelve months)

−$2.23

Book value per share

$7.11

P/E (trailing twelve months)

—

Price to book

22.59

Debt to assets

33.71%

Payout ratio

—

Dividend yield

—

Company profile

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

• Is Twist Bioscience (TWST) profitable?

  No. Twist Bioscience reported a net loss of $136.7M over the trailing twelve months.

• How much revenue does Twist Bioscience (TWST) make?

  Twist Bioscience generated $431.8M in revenue over the trailing twelve months, up 23.24% year over year.

• How do I buy stock in Twist Bioscience (TWST)?

  TWST trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.